Guggenheim Rates Bruker (BRKR) buy, $70 Price Target

Guggenheim maintains its optimistic view on Bruker with a $70 price target, a 16.32% upside from the current price.

By EarningsIQ Research Desk · Published Jun 29, 2026, 10:00 AM EDT · Updated Jul 1, 2026, 10:01 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Guggenheim rated Bruker Corporation ($BRKR) "buy" with a $70 price target on June 29, 2026.

Since the rating, $BRKR is up 2.7% after 1 week, up 3.4% after 1 month and down 8.2% to date (from the $59.66 close on Jun 29, 2026).

BRKR Bruker Corporation

$54.80 +14.26% year to date

Daily close · Oct 16, 2026

Key Points

Guggenheim reiterated its buy rating for Bruker Corporation with a $70 price target on June 29, 2026.
Guggenheim's $70 price target implies 16.32% upside from Bruker Corporation's ($BRKR) current $60.18 share price.
Shares of NasdaqGS:BRKR traded near $60.91 on Monday, with a market cap of approximately $9.27 billion.
Bruker insiders and analysts show varied activity, with insider buying and multiple firms maintaining ratings.

Get $BRKR trade alerts by text

We text you when insiders, Congress or big funds trade $BRKR. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Bruker Corporation alert may contain errors. Disclosures

Guggenheim reiterated its buy rating on Bruker Corporation (NASDAQ: BRKR) on June 29, 2026, setting a price target of $70. Analyst Subbu Nambi affirmed the firm's positive outlook on the company, which specializes in scientific instruments and analytical solutions.

Bruker Corporation Stock Down 1.9%

Shares of Bruker Corporation traded near $60.91 on Monday, reflecting a market capitalization of about $9.27 billion. The company operates with a forward P/E ratio of 25.0 and a beta of 1.302, indicating moderate market volatility. Over the past 52 weeks, the stock has seen a low of $28.53 and a high of $64.54. Its 50-day moving average is $47.91, while the 200-day moving average stands at $42.55.

12-month forecast

$BRKR price target

Bruker Corporation daily closes and this analyst's $70 target. Not advice.

Recent Earnings

Bruker Corporation reported revenue of approximately $3.46 billion, showing a modest growth of 2.7%. However, the company is not currently profitable, with a negative net margin of -0.34% and a return on equity of -0.43%. The next earnings release is scheduled for August 4, 2026.

Dividend

Bruker offers an annual dividend rate of $0.20 per share, with a dividend yield of 0.33%. The payout ratio is relatively low at 38.5%, suggesting the company retains a significant portion of its earnings for reinvestment.

Insider Buying and Selling at Bruker Corporation

On June 15, 2026, Mark Munch, Executive VP and President of Bruker Nano Inc., sold 2,000 shares at an average price of $54.76 and purchased 2,000 shares at $22.19. Thierry Bernard also bought 2,886 shares on May 15, 2026.

Analysts Set New Price Targets

On June 29, 2026, Guggenheim maintained its buy rating with a $70 price target. Barclays also maintained a buy rating with a $60 target on June 24, 2026. JP Morgan echoed the buy sentiment with a $65 target on June 8, 2026. The consensus recommendation is a buy, with an average target price of $53.83 among 12 analyst opinions.

About Bruker Corporation

Bruker Corporation, based in Billerica, Massachusetts, develops and distributes scientific instruments and analytical solutions. The company operates through several segments, including Bruker Scientific Instruments and Bruker Energy & Supercon Technologies. Its offerings include magnetic resonance spectroscopy, preclinical imaging, and life science tools. Founded in 1960, Bruker is led by CEO Dr. Frank H. Laukien and employs around 11,085 people.

Bottom Line

Guggenheim's reaffirmation of a buy rating on Bruker Corporation underscores continued confidence in the company's market position. While the stock has shown some volatility, it remains a focus for investors given its scientific instrumentation expertise. As always, it's important to remember that analyst ratings are just one piece of the puzzle, and investors should consider their own research before making decisions.